Short Interest in Milestone Pharmaceuticals Inc. (NASDAQ:MIST) Declines By 27.9%

Milestone Pharmaceuticals Inc. (NASDAQ:MIST) was the target of a large drop in short interest during the month of January. As of January 31st, there was short interest totalling 481,400 shares, a drop of 27.9% from the January 15th total of 667,900 shares. Based on an average trading volume of 612,900 shares, the days-to-cover ratio is presently 0.8 days.

Milestone Pharmaceuticals Trading Up 0.7 %

Shares of MIST stock traded up $0.02 during trading hours on Friday, reaching $2.31. The company’s stock had a trading volume of 215,881 shares, compared to its average volume of 749,249. The stock has a market capitalization of $122.93 million, a P/E ratio of -2.83 and a beta of 1.80. Milestone Pharmaceuticals has a one year low of $1.12 and a one year high of $2.75. The firm’s fifty day simple moving average is $2.03 and its 200 day simple moving average is $1.72. The company has a current ratio of 15.40, a quick ratio of 15.40 and a debt-to-equity ratio of 2.18.

Milestone Pharmaceuticals (NASDAQ:MIST) last issued its quarterly earnings data on Tuesday, November 12th. The company reported ($0.14) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.18) by $0.04. Equities research analysts expect that Milestone Pharmaceuticals will post -0.62 EPS for the current year.

Wall Street Analysts Forecast Growth

Separately, HC Wainwright restated a “buy” rating and set a $25.00 price target on shares of Milestone Pharmaceuticals in a research report on Monday, January 27th.

Institutional Investors Weigh In On Milestone Pharmaceuticals

Large investors have recently made changes to their positions in the business. Atria Investments Inc grew its holdings in shares of Milestone Pharmaceuticals by 44.4% in the third quarter. Atria Investments Inc now owns 40,421 shares of the company’s stock worth $61,000 after acquiring an additional 12,430 shares during the period. BML Capital Management LLC grew its holdings in shares of Milestone Pharmaceuticals by 3.0% in the third quarter. BML Capital Management LLC now owns 1,136,091 shares of the company’s stock worth $1,727,000 after acquiring an additional 33,196 shares during the period. PVG Asset Management Corp bought a new stake in shares of Milestone Pharmaceuticals in the third quarter worth $46,000. XTX Topco Ltd bought a new stake in shares of Milestone Pharmaceuticals in the fourth quarter worth $80,000. Finally, National Bank of Canada FI grew its holdings in shares of Milestone Pharmaceuticals by 163.4% in the fourth quarter. National Bank of Canada FI now owns 18,700 shares of the company’s stock worth $44,000 after acquiring an additional 11,600 shares during the period. 86.18% of the stock is currently owned by institutional investors.

About Milestone Pharmaceuticals

Milestone Pharmaceuticals Inc, a biopharmaceutical company, focuses on the development and commercialization of cardiovascular medicines. The company's lead product candidate is etripamil, a novel and potent calcium channel blocker, which is in Phase III clinical trial for the treatment of paroxysmal supraventricular tachycardia in the United States and Canada; and Phase II clinical trial for the treatment of atrial fibrillation and rapid ventricular rate.